Aventis Pharmaceuticals Inc.

Thaddeus Nieduzak

Sharon Anne Jackson

Yulin Chiang

Kenneth J Bordeau

John G Jurcak

Matthias Urmann

Horst Hemmerle

James Hendrix

Gregory Shutske

Joseph T Strupczewski

David Fink

George Lee

Nicola Collar

James P Carey

Paul Angell

Jean-Francois Sabuco

Jean Merrill

Guyan Liang

Xu-Yang Zhao

Franz J Weiberth

Paul Justin Mueller

Harpal Gill

Jean-Fancois Sabuco

Jospeh T Strupczewski

Sam Rebello

George E Lee

James A Hendrix

Jackson Sharon Anne Anne

Kenneth K Bordeau

Joseph T c/o Sanofi-Aventis US Inc Strupczewski

The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

[object Object]

The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands

The present invention relates to coumarins of the formula (I): that are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions and methods of using these compounds as inhibitors of nitric oxide synthase are described herein.

Coumarins as iNOS inhibitors

Growing community of inventors

Bridgewater, NJ, United States of America

Thaddeus Nieduzak